Breaking News, Collaborations & Alliances

Catalent Biologics Forms Agreement With Moderna Therapeutics

Designed to support cGMP clinical manufacturing of Moderna’s mRNA personalized cancer vaccine

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent Pharma Solutions has entered into an agreement with Moderna Therapeutics to support near-term clinical Good Manufacturing Practice (GMP) messenger RNA (mRNA) manufacturing efforts for Phase 1/2 clinical studies of the company’s mRNA personalized cancer vaccines. Moderna is a clinical stage biotechnology company pioneering mRNA Therapeutics to create a new generation of transformative medicines for patients. Moderna, in collaboration with Merck, is advancing mRNA-based personalized cance...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters